Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Spectral’s subsidiary prepares for demo

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Aug 25, 2021 11:00am

222 Views

Post# 33760903

RE:Spectral’s subsidiary prepares for demo

Cebanem wrote: Spectral's subsidiary (Dialco) prepares to present dialysis capabilities to DaVita Dialysis Centers

If true, it (will start to) make cents
“we’re always looking for new solutions that ease the burden on our patients,”

https://www.fiercebiotech.com/medtech/davita-fresenius-team-up-to-bring-dialysis-care-out-their-clinics-and-into-home

DaVita maintains over 2,800 brick-and-mortar dialysis centers in the U.S., while Fresenius’ North America subsidiary owns more than 2,500 on the continent—together accounting for more than 80% of the entire U.S. market.

MM

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks